Mariner
JSPR icon

Mariner’s Jasper Therapeutics JSPR Stock Holding History

Mariner’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,193
Closed -$29K – 3681
2025
Q3 		$29K Sell
12,193
-13,320
-52% -$40.4K ﹤0.01% 3490
2025
Q2 		$142K Sell
25,513
-5,677
-18% -$28K ﹤0.01% 3160
2025
Q1 		$134K Sell
31,190
-5,604
-15% -$37.3K ﹤0.01% 3128
2024
Q4 		$787K Sell
36,794
-5,412
-13% -$113K ﹤0.01% 1824
2024
Q3 		$794K Sell
42,206
-5,122
-11% -$102K ﹤0.01% 1780
2024
Q2 		$1.07M Sell
47,328
-5,498
-10% -$132K ﹤0.01% 1459
2024
Q1 		$1.55M Sell
52,826
-6,225
-11% -$111K ﹤0.01% 1238
2023
Q4 		$466K Sell
59,051
-6,224
-10% -$41.8K ﹤0.01% 1982
2023
Q3 		$457K Sell
65,275
-6,225
-9% -$76K ﹤0.01% 1843
2023
Q2 		$980K Buy
+71,500
New +$1.06M ﹤0.01% 1324

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mariner's JSPR Position: Q4 2025 in Review

Mariner sold out of Jasper Therapeutics (JSPR) in Q4 2025, closing a stake of 12,193 shares — an estimated $29K sold.

Mariner first reported a position in JSPR in Q2 2023 and held it in 10 quarters. The position peaked at $1.55M in Q1 2024. 55 funds tracked by Wall St. Rank hold JSPR as of Q4 2025.

  • Mariner reported no remaining Jasper Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mariner sold 12,193 Jasper Therapeutics shares in Q4 2025, an estimated $29K.
  • Mariner first reported a position in Jasper Therapeutics in Q2 2023 and held it in 10 quarters.
  • Mariner's Jasper Therapeutics position peaked at $1.55M in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.